SCA
Spearhead Capital Advisors Portfolio holdings
AUM
$92.3M
This Quarter Return
+7.56%
1 Year Return
-18.16%
3 Year Return
+25.24%
5 Year Return
+54.04%
10 Year Return
–
AUM
$735M
AUM Growth
+$735M
(+8.5%)
Cap. Flow
+$18.1M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
31.1%
Holding
195
New
10
Increased
148
Reduced
29
Closed
4
Top Buys
| 1 |
Sherwin-Williams
SHW
|
$6.02M |
| 2 |
Golub Capital BDC
GBDC
|
$2.31M |
| 3 |
Apple
AAPL
|
$1.32M |
| 4 |
Bloom Energy
BE
|
$1M |
| 5 |
ETRACS Alerian MLP Infrastructure Index ETN Series B due April 2, 2040
MLPB
|
$590K |
Top Sells
| 1 |
Kiniksa Pharmaceuticals
KNSA
|
$1.98M |
| 2 |
Moderna
MRNA
|
$651K |
| 3 |
Alphabet (Google) Class C
GOOG
|
$632K |
| 4 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$576K |
| 5 |
GLUU
Glu Mobile Inc.
GLUU
|
$503K |
Sector Composition
| 1 | Technology | 15.29% |
| 2 | Healthcare | 12.02% |
| 3 | Consumer Staples | 10.97% |
| 4 | Financials | 10.35% |
| 5 | Communication Services | 7.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Zillow
Z
$20.4B
| $384K | 0.05% |
3,139
+410
| +15% | +$50.2K |
|
152
eHealth
EHTH
$118M
| $383K | 0.05% |
6,555
+632
| +11% | +$36.9K |
|
153
Fastly
FSLY
$1.12B
| $380K | 0.05% |
+6,377
| New | +$380K |
|
154
Quanterix
QTRX
$211M
| $379K | 0.05% |
6,464
+1,029
| +19% | +$60.3K |
|
155
CRISPR Therapeutics
CRSP
$4.71B
| $374K | 0.05% |
2,310
-1,396
| -38% | -$226K |
|
|
156
Moderna
MRNA
$9.37B
| $372K | 0.05% |
1,583
-2,771
| -64% | -$651K |
|
157
Corcept Therapeutics
CORT
$7.35B
| $367K | 0.05% |
16,692
+2,487
| +18% | +$54.7K |
|
|
PLAN
158
DELISTED
Anaplan, Inc.
PLAN
| $364K | 0.05% |
6,835
+926
| +16% | +$49.3K |
|
159
Guardant Health
GH
$8.41B
| $363K | 0.05% |
2,925
+322
| +12% | +$40K |
|
160
EverQuote
EVER
$849M
| $362K | 0.05% |
11,068
+1,641
| +17% | +$53.7K |
|
161
Vanguard Long-Term Corporate Bond ETF
VCLT
$6.7B
| $355K | 0.05% |
3,316
+377
| +13% | +$40.4K |
|
162
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $354K | 0.05% |
25,608
+4,179
| +20% | +$57.8K |
|
|
OTRK
163
DELISTED
Ontrak
OTRK
| $354K | 0.05% |
10,911
+2,999
| +38% | +$97.3K |
|
164
Vanguard Long-Term Treasury ETF
VGLT
$9.84B
| $352K | 0.05% |
4,010
+383
| +11% | +$33.6K |
|
165
Karyopharm Therapeutics
KPTI
$61.7M
| $351K | 0.05% |
34,029
+7,006
| +26% | +$72.3K |
|
166
Ocular Therapeutix
OCUL
$2.12B
| $342K | 0.05% |
24,134
+3,853
| +19% | +$54.6K |
|
|
NVTA
167
DELISTED
Invitae Corporation
NVTA
| $341K | 0.05% |
10,108
+1,703
| +20% | +$57.5K |
|
168
PTC Therapeutics
PTCT
$3.92B
| $337K | 0.05% |
7,962
+1,463
| +23% | +$61.9K |
|
169
iShares ESG Aware MSCI EM ETF
ESGE
$5.09B
| $327K | 0.04% |
7,249
+36
| +0.5% | +$1.62K |
|
170
NVIDIA
NVDA
$4.24T
| $327K | 0.04% |
409
-229
| -36% | -$183K |
|
171
Illumina
ILMN
$15.8B
| $326K | 0.04% |
689
-43
| -6% | -$20.3K |
|
172
Vanguard Materials ETF
VAW
$2.9B
| $317K | 0.04% |
1,753
-130
| -7% | -$23.5K |
|
173
iRhythm Technologies
IRTC
$5.46B
| $316K | 0.04% |
4,768
+2,789
| +141% | +$185K |
|
174
Ultragenyx Pharmaceutical
RARE
$2.89B
| $316K | 0.04% |
3,318
+550
| +20% | +$52.4K |
|
175
Acadia Pharmaceuticals
ACAD
$4.38B
| $311K | 0.04% |
+12,751
| New | +$311K |
|